Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.44 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.42 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998230 | 0.98 | POLRMT (0.50) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL4765352 | 0.92 | POLRMT (0.53) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL20078675 | 0.91 | POLRMT (0.43) | POLRMTENTPD1P2RY1SRCP2RY2 | |
| SCHEMBL10120066 | 0.88 | P2RY2 (0.41) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL23034475 | 0.86 | POLRMT (0.41) | POLRMTP2RX1P2RX3P2RX4P2RY2 | |
| SCHEMBL19223073 | 0.86 | POLRMT (0.41) | POLRMTP2RX1P2RX3P2RX4P2RY2 | |
| Rdv-Tp SCHEMBL23278555 | 0.85 | POLRMT (0.51) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL10120078 | 0.85 | POLRMT (0.51) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL23711110 | 0.85 | POLRMT (0.51) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| Rdv-Tp SCHEMBL24492745 | 0.85 | POLRMT (0.51) | POLRMTP2RX1P2RX3P2RX4P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | GILEAD SCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175805-A1 | REMDESIVIR TREATMENT METHODS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2595980-B1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | POLRMT 49/4885P2RX1 1465/4885P2RX3 1395/4885 |
| US-20220175805-A1 | REMDESIVIR TREATMENT METHODS | EIF2AK2, MTAP, ACE | POLRMT 44/4885P2RX1 2072/4885P2RX3 2485/4885 |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | POLRMT 148/4885P2RX1 169/4885P2RX3 341/4885 |
| US-20230233587-A1 | REMDESIVIR TREATMENT METHODS | EIF2AK2, MTAP, ACE | POLRMT 44/4885P2RX1 2072/4885P2RX3 2485/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | POLRMT 148/4885P2RX1 169/4885P2RX3 341/4885 |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | POLRMT 148/4885P2RX1 169/4885P2RX3 341/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | POLRMT 1645/4885P2RX1 2471/4885P2RX3 3004/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | POLRMT 148/4885P2RX1 169/4885P2RX3 341/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | POLRMT 450/4885P2RX1 1051/4885P2RX3 1739/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | POLRMT 450/4885P2RX1 1051/4885P2RX3 1739/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | POLRMT 1679/4885P2RX1 2456/4885P2RX3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.